Existing market research reports have shown that the diffusion of existing diagnostic lung cancer tests—which according to the molecular testing guidelines of the International Association for the Study of Lung Cancer are mainly EGFR and ALK—is still low ([7], Pfizer Inc., New York, NY, USA, data on file [8]). The gene discussed is EGFR; the disease is lung carcinoma.